AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04476667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Psychotherapy
Description: Module Content: The first 3 sessions will be designed to address the symptoms caused by fear of illness or concerns about personal safety in the context of pandemic. Electronic-CBT (e-CBT) modules will focus on problem solving techniques, with mindfulness practices included, to help build healthy coping skills to address the uncertainties surrounding the COVID-19 pandemic. e-CBT modules will involve guiding participants to develop constructive and balanced coping strategies through 5 focuses: stimulus control, cognitive therapy, sleep hygiene, relaxation therapy, and sleep restriction. Additional focus will be placed on the connection between thoughts, behaviours, emotions, physical reaction and one's environment.
Study NCT04231448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone)
Description: R-CHOP : rituximab 375 mg/m2 IV, cyclophosphamide 750 mg/m2 IV, doxorubicin 50 mg/m2 IV, vincristine 1.4 mg/m2 IV \[maximum total 2 mg\], and prednisone \[or equivalent\] 100 mg orally as the background therapy for 6 cycles (21 days/cycle).
Study NCT04231448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: R-CHOP(Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone)
Description: R-CHOP : rituximab 375 mg/m2 IV, cyclophosphamide 750 mg/m2 IV, doxorubicin 50 mg/m2 IV, vincristine 1.4 mg/m2 IV \[maximum total 2 mg\], and prednisone \[or equivalent\] 100 mg orally as the background therapy for 6 cycles (21 days/cycle).
Study NCT04231448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucidinostat
Description: Tucidinostat ：30 mg was given orally after breakfast on day 1, day 4, day 8, day 11 in a 21-day cycle，for 6 cycles. After cycle 6 patients who are evaluated as complete response will receive 24 weeks additional administrations of Tucidinostat on day 1, day 4, day 8, day 11 in a 21-day cycle.
Study NCT04231448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo：30 mg was given orally after breakfast on day 1, day 4, day 8, day 11 in a 21-day cycle，for 6 cycles. After cycle 6 patients who are evaluated as complete response will receive 24 weeks additional administrations of placebo on day 1, day 4, day 8, day 11 in a 21-day cycle.
Study NCT01829568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT01829568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01829568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT01829568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01829568 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT03433976 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: spinal anesthesia
Description: spinal anesthesia for planned cesarean sections
Study NCT03433976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia
Description: spinal anesthesia for planned cesarean sections
Study NCT00632749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 811283 (d 1 and 15)
Description: BI 811283 (24 hours i.v.c.i.) on day 1 and 15 of a 4-week treatment cycle
Study NCT00632749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 2 x 20 mg/d s.c. on days 1-10 of a 4-week treatment cycle
Study NCT00632749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 811283 (d1)
Description: BI 811283 (24 hours i.v.c.i.) on day 1 of a 4-week treatment cycle
Study NCT03091361 — intervention group
Intervention type: OTHER
Intervention: imaging, no intervention
Description: no intervention
Study NCT03899350 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT02814188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate Beverage
Description: 750 ml of a 13.5% carbohydrate (sucrose) beverage
Study NCT02814188 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Beverage
Description: 750 ml of an artificially-sweetened beverage
Study NCT03083782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban alone
Description: A single dose of 10 mg apixaban administered orally at 0H on Day 1.
Study NCT03083782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Once daily dose of 100 mg cyclosporine administered orally on Days 1 to 3.
Study NCT03083782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Once daily dose of 5 mg tacrolimus administered orally on Days 1 to 3.
Study NCT03083782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: A single dose of 10 mg apixaban administered orally on Day 3 immediately following cyclosporine
Study NCT03083782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: A single dose of 10 mg apixaban administered orally on Day 3 immediately following tacrolimus
Study NCT01734096 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower body negative pressure (LBNP)
Description: Lower limbs are put in in LBNP device for one hour (-30 mbar)
Study NCT03373448 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Labrida BioClean
Description: The implant pockets will be debrided with the BioClean™ biodegradable brush for 2 minutes and with the brush seated in an oscillating dental handpiece (NSK ESQ10 TEQ) and thereafter irrigated with sterile saline or commercially available and area-specific titanium curettes (Langer and Langer, Rønvig) for 2 minutes and thereafter irrigated with sterile saline. The treatment will be repeated every three months until the terminal examination after 24 months. Debridement is performed with local anaesthesia as needed. Healthy sites will not be retreated.
Study NCT03373448 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Titanium curettes
Description: Peri-implant pockets will be debrided using titanium curettes.
Study NCT00168753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alefacept
Description: IM
Study NCT00785915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6765
Description: single administration and once daily for 5 days
Study NCT00785915 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single administration and once daily for 5 days
Study NCT02258815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ch14.18/CHO
Description: A six courses regimen consisting of a 8 hour infusion (ch14.18/CHOmAb 20 mg/m² ) for five consecutive days will be administered every 4 weeks.~Interleukin 2 will be added to cycles 4-6 at days 6,8,10 (1 x 106 IU/m²/d s.c.) Participants will be premedicated with an intravenous antihistamine and ranitidine within approximately 30 minutes prior and during the infusion of the study agent Pain as an anticipated side effect is managed by a standard pain prophylaxis with Morphium hydrochloride Disease status will be evaluated after 3 and 6 courses and after 1 year.
Study NCT02988037 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A-DBT-A
Description: Adapted Dialectical Behaviour Therapy for Adolescents
Study NCT01805830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP513
Description: form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
Study NCT01734096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan cilexetil
Description: candesartan cilexetil 16 mg once a day for 7 days cross over with placebo in control group, obesisty group and white coat hypertension group
Study NCT01805830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
Study NCT01045174 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nebulizer (breath-actuated versus conventional continuous-output)
Description: Participants are randomly assigned to receive bronchodilator treatments for asthma according to the standard of care using either a breath-actuated nebulizer device or a conventional continuous-output nebulizer. Standard unit doses of albuterol/ipratropium bromide or albuterol are used in both devices.
Study NCT02299310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan 80mg/tablet, 1 tablet once daily (crossover)
Study NCT02299310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril
Description: Perindopril 4mg/tablet, 1 tablet once daily (crossover)
Study NCT04442893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rumination-Focused Cognitive Behaviour Therapy
Description: Rumination-Focused Cognitive Behavioural Therapy(RFCBT) is based on a differentiation between functional and dysfunctional styles of perseverative thinking with the helpful style characterized as a concrete, process-focused and specific style of thinking and the idea that rumination is a habit maintained by negative reinforcement. In line with the theoretical assumptions, RFCBT combines strategies from behavioral activation with strategies to foster concrete, process-focused and specific thinking.
Study NCT04442893 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Health Education programme
Description: Health education programme would be any planned activity or set of activities aimed at increasing health literacy and developing life skills conducing to health (e.g. decision making, problem solving, critical thinking, interpersonal skills, stress management, coping with emotions).
Study NCT02045784 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Infant formula
Description: To establish dose-response relationships, formula-fed infants will be randomly allocated to three 11-day cross-over periods of exclusive consumption of infant formula providing different amounts of iodine. All iodine levels are within the required iodine levels for infant formula following the regulations of the United States, the European Union, Switzerland and New Zealand.
Study NCT02045784 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Breast milk
Description: Unlimited breast feeding
Study NCT02512380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel;oxaliplatin;s1
Description: Docetaxel 60mg/m2 was administered on day 1 of every 14 days.oxaliplatin 85 mg/m2 was administered on day 2 every 14 days. 40-60 mg of oral S-1 according to body-surface area twice a day was given for 10 days every 14 days .
Study NCT02512380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin;s1
Description: oxaliplatin 100 mg/m2 on day 1 every 21 days.40-60 mg of oral S-1 according to body-surface area twice a day was given for 2 weeks every 21 days .
Study NCT04222192 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Epidural block
Description: Epidural catheter insertions
Study NCT04222192 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epidural block
Description: Epidural catheter insertions
Study NCT03988946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Mitral Valve Replacement via Transseptal Access
Description: The Cephea Transseptal Mitral Valve System is intended for use in symptomatic patients with moderate to severe degenerative or functional mitral regurgitation, who are poor candidates for surgery and who are anatomically eligible for the treatment.
Study NCT02336386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CDD
Description: Chemotherapy
Study NCT02336386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDD Plus Bortezomib
Description: Chemotherapy plus Proteasome Inhibitors
Study NCT00763152 — intervention group
Intervention type: OTHER
Intervention: Observation of transponder stability
Description: Observation of transponder stability and placement in the prostatic bed following radical prostatectomy
Study NCT03284346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo CARE
Study NCT03284346 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Undergo standard stretching program
Study NCT03284346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03284346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03284346 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring Device
Description: Receive Polar heart rate monitor
Study NCT03284346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03284346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03284346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03284346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03587870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enteral nutrition with Fresubin Intensive
Description: Comparison of intermittent (experimental) vs continuous (standard, active comparator) enteral nutrition on muscle wasting in critically ill patients
Study NCT03587870 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enteral nutrition with Fresubin Intensive
Description: Comparison of intermittent (experimental) vs continuous (standard, active comparator) enteral nutrition on muscle wasting in critically ill patients
Study NCT03989752 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Robotic Exoskeleton for Ambulation
Description: 16-week walking program (34 sessions) with an overground walking robotic exoskeleton guided by a certified physical therapist
Study NCT01873443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, MTX, folic acid
Description: Rituximab IV 1000mg MTX 10\~25mg/week Folic acid at least 5mg/week
Study NCT02716194 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX 826
Study NCT02716194 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Octocog alfa
Study NCT00716638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-focused Cognitive Behavior Therapy
Description: This intervention comprises 10 sessions of trauma-focused cognitive behavior therapy for PTSD with the components (a) prolonged imaginal exposure, (b) in vivo exposure, and (c) cognitive restructuring.
Study NCT00716638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Description: This intervention comprises 10 sessions of EMDR according to the standard protocol.
Study NCT00361894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY59-7939)
Description: 10 mg rivaroxaban (tablet) once daily administered for 13 +/- 2 days
Study NCT00361894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Syringe of enoxaparin at a dose of 40 mg for 13 +/- 2 days
Study NCT00537264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health-related quality of life assessment
Description: Study participants will be asked to complete the following health-related quality of life questionnaires: EQ-5D, Health Utilities Index 3, SF-8 and SF-6D. The Singapore (Chinese) versions of these questionnaires have been previously tested and validated in a pilot cohort of the same study population.
Study NCT04733001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSG4112
Description: Once-daily oral administration
Study NCT01193816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loxapine
Description: Each patient may receive a maximum dosage of 900mg of Loxapine per day (drinkable solution through gastric probe) or the same volume of placebo. 2 initial administrations of 150 mg followed by potential readministration of 100 mg of loxapine. Maximum duration of treatment will be 14 days.The dosage by day is defined by patients' clinical condition, assessed with RASS score.
Study NCT01193816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01108562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Patients in the experimental group will be receiving a Lidocaine infusion at 1.33 mg/kg/hr for 24 hours postoperatively.
Study NCT01376817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fat emulsion with MCT, LCT, olive oil and omega 3 fatty acids
Description: 40% of non-protein calories (25-30 kcal/kg/day) of total parenteral nutrition, IV (in the vein), from day 1 to day 10
Study NCT01376817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fat emulsion with MCT and LCT
Description: 40% of non-protein calories (25-30 kcal/kg/day) of total parenteral nutrition, IV (in the vein), from day 1 to day 10
Study NCT02717325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.(Formulation- SR16-08)
Study NCT01108562 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Patients in the control group will be receiving an infusion of normal saline for 24 hours postoperatively.
Study NCT01811381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Subjects will take 800 mg of curcumin in 4 capsules BID per day prior to meals
Study NCT01811381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: Subjects will take 800 mg of curcumin in 4 capsules BID per day prior to meals
Study NCT04324593 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral intravenous analysis (PIVA) algorithm
Description: An IV line with an attached Deltran BP transducer will be used together with LabChart software to record venous waveforms during various interventions. These waveforms will be processed using the PIVA algorithm and the calculated values will be compared to those from Nellcor respiratory monitor, Capnograph and cardiac telemetry monitoring.
Study NCT01598441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloprost nebuliser solution
Description: Iloprost nebuliser solution 500 ng/kg inhaled(10 min recommended) q3h for 2 days
Study NCT01598441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: distilled water
Description: 1-2 ml aerosolized distilled water inhalation per session
Study NCT02145026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin beta
Description: Epoetin beta 30,000 or 60,000 IU per week SC injection
Study NCT02541162 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral information and interviews
Description: interviews about sexuality and self experience during the disease
Study NCT04102813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Therapy
Description: It consists in a group of body-mind techniques based on functional theory developed in Italy by prof. Luciano Rispoli. These techniques are oriented to stimulate a diaphragmatic breathing though a thoracic and abdominal manipulation, with the aim to activate the parasympathetic nervous system and therefore reducing inflammation
Study NCT01739621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex 12 mg
Study NCT01739621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex 24 mg
Study NCT02185313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: visual stimulus to follow
Study NCT00103311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ispinesib
Description: Given IV
Study NCT00103311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03480126 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Herbal Teas
Description: Steeped tea ingested 3 times a day for 3 mos
Study NCT03480126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herbal Teas
Description: Steeped tea ingested 3 times a day for 3 mos
Study NCT02944370 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PlayFit - modified exercise games
Description: Play modified games with other adults three times a week for 12 weeks. Complete a brief survey on the games played and program satisfaction.
Study NCT01802788 — intervention group
Intervention type: DEVICE
Intervention: St Jude Medical Portico replacement aortic valve
Study NCT01802788 — intervention group
Intervention type: PROCEDURE
Intervention: Transcatheter Aortic Valve Implant
Study NCT04229888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LipiFlow
Description: Medical device that applies a combination of heat and pressure to the inner eyelid to remove gland obstructions and stagnant gland content
Study NCT04229888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Based (Sham) Treatment
Description: A light based (sham) treatment will be used to compare effectiveness to the LipiFlow treatment.